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Purpose: To create a clinically viable dose-volume histogram (DVH) estimation model using the Varian
RapidPlan (Varian Medical Systems, Palo Alto USA) knowledge based planning (KBP) platform. This model
aims to evaluate locally advanced rectal cancer with 6X IMRT, and was developed on a plan database taken
from the RTOG 0822 national clinical trial. This is the first multi-institutional 6X IMRT dose estimation
model designed using RapidPlan. The effectiveness of the model as a dosimetry quality assurance (QA) tool
was evaluated.
Methods: Treatment plans submitted to the RTOG 0822 clinical trial were dosimetrically evaluated for plan
quality. Plans whose DVH statistics met RTOG 0822 target criteria were identified as high-quality, and were
used in the initial training sample for the model. Of the 97 IMRT plans enrolled in the trial, 58 were treated
with only 6X photons, and 26 of those were identified as high-quality plans. All 6X enrolled plans were
iteratively re-optimized with the model to test clinical effectiveness, evaluate the model as a tool for treatment
planning QA, and continuously expand the model’s training sample. Re-optimized plans which met target
criteria were added to the training sample, resulting in a total of 40 geometries in the training sample.
Results: The rectal IMRT RapidPlan model created in this paper was shown to accurately predict estimated
DVH bands for all viable high-quality plans enrolled in the clinical trial. The model was also able improve the
DVH statistics for a significant majority of the low-quality plans enrolled in the clinical trial.
Conclusion: The RapidPlan rectal 6X IMRT model created in this study can be used as an effective tool for
dosimetry QA and initial plan creation.
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Abstract 
 
Purpose: To create a clinically viable dose-volume histogram (DVH) estimation model using the 
Varian RapidPlan (Varian Medical Systems, Palo Alto USA) knowledge based planning (KBP) 
platform.  This model aims to evaluate locally advanced rectal cancer with 6X IMRT, and was 
developed on a plan database taken from the RTOG 0822 national clinical trial.  This is the first 
multi-institutional 6X IMRT dose estimation model designed using RapidPlan.  The 
effectiveness of the model as a dosimetry quality assurance (QA) tool was evaluated. 
Methods: Treatment plans submitted to the RTOG 0822 clinical trial were dosimetrically 
evaluated for plan quality.  Plans whose DVH statistics met RTOG 0822 target criteria were 
identified as high-quality, and were used in the initial training sample for the model.  Of the 97 
IMRT plans enrolled in the trial, 58 were treated with only 6X photons, and 26 of those were 
identified as high-quality plans.  All 6X enrolled plans were iteratively re-optimized with the 
model to test clinical effectiveness, evaluate the model as a tool for treatment planning QA, and 
continuously expand the model’s training sample.  Re-optimized plans which met target criteria 
were added to the training sample, resulting in a total of 40 geometries in the training sample. 
Results: The rectal IMRT RapidPlan model created in this paper was shown to accurately 
predict estimated DVH bands for all viable high-quality plans enrolled in the clinical trial.  The 
model was also able improve the DVH statistics for a significant majority of the low-quality 
plans enrolled in the clinical trial. 
Conclusion: The RapidPlan rectal 6X IMRT model created in this study can be used as an 
effective tool for dosimetry QA and initial plan creation. 
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1 Introduction 
 
Colorectal cancer is the third most commonly 
diagnosed cancer among the worldwide 
populace, ranking in as the second most 
common cancer for women and the third most 
common cancer for men.  While the current 
mortality rate for colorectal cancer is relatively 
low at 8.5%, studies suggest a rise in rectal 
cancer mortality due to increasing rates of late-
stage discovery of the disease [1,2].  Because 
rectal cancers are often discovered at these later 
stages where more extra-rectal tissue is 
encompassed in the PTV, reducing toxicity to 
surrounding organs is a primary objective of any 
rectal radiotherapy plan [3].  Due to these 
overlapping volumes, IMRT is highly preferred 
over traditional 3D conformal therapy 
(3DCRT), and has been shown to provide 
significant clinical advantages with reduced 
organ at risk (OAR) dose [4]. 
While the malleable dose distributions 
possible with IMRT planning has allowed for 
more personalized treatment plans as compared 
to 3DCRT, it has also resulted in greater user-
dependency and quality variance across clinics 
[5,6].  In addition to beam angle and isocenter 
location, dosimetrists must also account for 
placement and prioritization of optimization 
goals, a task which relies heavily on the user’s 
level of experience.  More practiced planners 
can know what DVH they can reasonably 
achieve from a given patient geometry, whereas 
others may not reach the most desirable solution 
within the clinical timeframe.  This uncertainty 
in treatment planning, paired with the lack of 
QA checks on plan optimality, results in an 
unnecessary increase of patient risk and normal 
tissue complications [7].  Thus, there is a need 
for technologies that can not only reduce plan 
quality variability, but can also be easily 
implemented in smaller clinics with potentially 
less experienced staff. 
Varian’s solution to this problem is 
RapidPlan (Varian Medical Systems, Palo Alto, 
USA), a knowledge based planning (KBP) 
software that is easily integrated with the Aria 
record and verify system (RVS) and the Eclipse 
treatment planning system (TPS).  KBP 
programs are designed to learn what dose 
distributions are achievable by studying a 
submitted set of high-quality treatment plans in 
order to predict an optimized DVH for any 
given patient with a similar tumor.  When a 
treatment plan is submitted to the KBP as 
learning material, the KBP correlates the treated 
gantry angles and patient geometry (input) with 
the DVH statistics to the segmented organs 
(output).  Principal Component Analysis (PCA) 
is used to characterize the most salient features 
of the patient anatomy, and these features are 
correlated with segmented organ DVH via 
Support Vector Regression (SVR) [8].   
Once these correlations are calculated, the 
KBP model has effectively learned from its 
library, and can produce DVH estimations with 
consistently good optimality [9].  Despite these 
benefits and ease of use, KBP’s such as 
RapidPlan inextricably need a large library of 
high-quality plans to produce well-trained 
models.  While this can be a challenge for new 
or smaller clinics with a limited patient backlog, 
this need produces renewed opportunities to 
utilize the data submitted to massive clinical 
trials, such as the RTOG.  Data suggests that 
compliance with RTOG criteria is associated 
with increased survival rates, so it is suggested 
that the library for a given RapidPlan model is 
created from plans that meet these criteria [10]. 
RTOG 0822 is a phase II clinical trial that 
studied the decrease in gastrointestinal toxicity 
when IMRT is used for preoperative 
chemoradiotherapy as compared to traditional 
3DCRT, as studied in RTOG 0247 [11].  
Clinical plans enrolled in this trial treated 45 Gy 
IMRT to the rectum and draining lymphatics at 
risk followed by a 5.4 Gy 3DCRT boost at 1.8 
Gy daily fractions.  The study closed December 
2016 with 79 patients accrued with a total 97 
therapy plans [12].  It should be noted that only 
the 6X IMRT plans submitted to this study were 
used in RapidPlan model created in this paper. 
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This paper discusses a rectal 6X IMRT 
model trained on a library of high-quality plans 
from RTOG 0822.  The model was tested for 
planning QA and DVH improvement using 
plans enrolled in the clinical trial.   
 
2 Theory 
 
2.1 Knowledge Based Planning 
 
While the software behind it is moderately 
complex, KBP is designed to behave very much 
like a human treatment planner.  A collection of 
plans is submitted to the KBP as learning 
material, with DVH’s the user has defined as 
optimal and should be replicated.  From these 
high-quality plans, the KBP correlates 
geometric features with attainable dose 
distributions, and can predict an optimal dose 
distribution for a new patient geometry.  In this 
way, the KBP acts as an automatic, easily 
understood second check on inverse planning 
optimization, allowing the user to see another 
optimization route or possibilities for further 
plan quality improvement.  Similarly, KBP can 
be used as a first step in creating a clinically 
viable plan or evaluating the differences 
between gantry angle combinations with little 
effort needed.  Indeed, KBP can be used to great 
effect in clinics that want or need that extra bit 
of manpower when it comes to creating or 
verifying treatment plans. 
This study specifically uses the Varian 
RapidPlan KBP program, available in Eclipse 
version 13.6.5.  RapidPlan utilizes PCA to 
identify the most important geometric features 
for quick DVH correlation and estimation. 
 
2.2 Principal Component Analysis 
 
Correlating a patient-gantry geometry with a 
three-dimensional dose distribution poses a 
multitude of challenges.  These geometries tend 
to be highly complex, unique to the given 
patient, and maintain a high voxel resolution, 
resulting in a large, high-dimensional dataset 
that cannot be effectively compressed without 
losing significant data.  However, this geometry 
can be characterized by extracting the most 
salient features using PCA.  This effectively 
reduces the dimensions of the data, allowing for 
substantially fewer calculations and correlations 
to relate patient geometries with dose 
distributions. 
Varian’s RapidPlan KBP software creates a 
dose-to-target histogram (DTH) for each OAR 
to use alongside PTV and OAR DVH’s during 
PCA calculation.  A DTH shows the fractional 
overlap between an OAR and a virtual volume 
symmetrically extended out from the PTV by a 
given distance.  A negative distance value 
indicates OAR/PTV overlap, and this overlap 
approaches 100% at an increased PTV 
expansion distance, as seen in Figure 1. 
 
 
Figure 1: Sample DTH graphic from Zhu et al [8] 
 
For each OAR and the m number of plans 
within the learning library, the DVH and DTH 
is sampled m times to creates a m-dimensional 
component vector known as a feature point.  In 
many studies that aim to develop KBP’s, such 
as Zhu et al [8], an m = 50 is used.  A component 
vector for each plan populates an n dimensional 
feature space specific for each OAR.  The 
coordinate system of the feature space is shifted 
such that the coordinate origin represents the 
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average feature value, and points within the 
space represent deviation from the mean.  These 
feature points are also normalized such that the 
standard deviation of point distance about the 
mean equals 1.  A m x m covariance matrix of 
these n points in this new coordinate system is 
then created, and singular value decomposition 
is performed to yield m eigenvectors and 
eigenvalues.  These eigenvectors form a PC 
coordinate system that identifies the principal 
components (PC’s), where the corresponding 
eigenvalues represent the amount of variation in 
a given component.  Thus, the principal 
components can be chosen for use in model 
training based on their variation, where 
components with larger variations in DVH and 
DTH yield more significant geometric data.  
This sophisticated feature selection among the 
m dimensional data allows for simplified data 
representation with significant reduction of 
calculation overhead [13]. 
Upon identification of the principal 
components representing the dosimetry and 
geometric data, SVR is used to map the 
correlations and allow for DVH estimation.  A 
patient DVH can be predicted by extracting the 
principal components from an input geometry 
and applying the inverse rotation and translation 
to this space to revert back to the original feature 
space which constructed the correlation map 
[8]. 
 
2.3 RapidPlan 
 
Varian RapidPlan offers a user-friendly KBP 
platform that consistently estimates high-
quality treatment plans.  Models created in 
RapidPlan are modality and site specific, 
performing best if they have a large library of 
plans with similar OAR sets.  Salient geometric 
features are extracted for each plan in the library 
using PCA and correlation with dosimetric 
features via SVR.   
When RapidPlan uses these correlations to 
predict the dose distributions for a new plan, 
estimated DVH (EDVH) bands are created for 
the segmented and assigned OAR’s.  The center 
of the band represents the median EDVH, and 
the band stretches out one deviation away from 
this median.  For OAR’s, a two-dimensional 
line exists within the bottom half of this band as 
a continuous optimization line objective.  As 
seen in Figure 2, this provides a useful visual 
marker for users to understand what OAR 
sparing they can expect from a given plan before 
any IMRT optimization takes place.   
 
 
Figure 2: DVH, EDVH, and optimization line for rectal 
IMRT optimized within RapidPlan during IMRT 
optimization.  The organs shown in this figure are the 
PTV (blue), bladder (yellow), small bowel (brown), left 
femoral head (purple), and right femoral head (green). 
 
Along with showing what the user can 
expect out of a given plan, visualizing the 
EDVH’s can also alert the user to the limitations 
of a plan created in RapidPlan.  Since the EDVH 
designates what is expected based on 
correlations formed from the learning library, 
the plans and geometries submitted to the 
library have a lasting effect on the model’s 
effectiveness.  If a model’s library largely 
consists of plans with little PTV/OAR overlap, 
then the model will not explicitly know how to 
account for geometries with significant 
PTV/OAR overlap, and will produce an 
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undesired EDVH.  During dose estimation, this 
is often visualized for the user via warning 
messages, very thin EDVH bands, or jagged 
optimization objective lines.  Thus, it is 
important to include a variety of patient 
geometries within the training library to ensure 
a wide coverage of patient anatomy and avoid 
model overtraining for specific geometries. 
RapidPlan has a variety of built-in tools to 
assist users in understanding the statistics and 
possible limitations of a given model.  Within 
the RapidPlan module built into Aria, users can 
view a summary of training results with 
goodness of correlation results and outlier 
statistics, as well as organ-specific plots of 
DVH’s, geometric statistics, DVH-geometric 
correlation regressions, and EDVH-DVH 
residual plots (where linearity indicates good 
dosimetric estimation and successful model 
training).   
Using these tools, users can readily 
determine issues with the model as a whole, as 
well as with a particular submitted plan.  If a 
user finds that the EDVH consistently 
underperforms for a given DVH region, they 
can put in a manual point optimization 
objective, similar to standard IMRT planning.  
This will be used in the model alongside the 
EDVH.  The user can either manually set the 
priority of the point objective or allow the 
model to estimate its priority for a given patient 
geometry. 
 
 
 
 
 
Figure 3: Femoral heads regression plot for RapidPlan 
model created in this paper 
 
3 Method 
 
3.1 Dosimetric Analysis of RTOG 0822 
Plan Library 
 
6X IMRT plans submitted to the RTOG 0822 
clinical trial were evaluated for plan quality 
before being used to create the initial iteration 
of the model described in this paper.  Plan 
quality was determined by DVH adherence to 
the target criteria specified in the RTOG 
protocol.  The radiation treatment criteria of a 
national trial, such as the RTOG, consists of 
dosimetric target parameters for both the target 
and relevant OAR’s.  The RTOG 0822 target 
criteria specified that the IMRT dose must meet 
a minimum PTV dose alongside maximum dose 
constraints for the bladder, femoral heads, small 
bowel, and PTV.  Along with target criteria, 
acceptable variation criteria is described to 
allow for slight deviation in parameter 
compliance and plan quality.  These criteria sets 
are tabulated in Table 1.   
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Table 1: IMRT DVH target and acceptable variation parameters for the RTOG 0822 clinical trial 
Minimum Dose Thresholds 
Structure Criteria Volume (%) Target Dose (Gy) Acceptable Dose (Gy) 
PTV 98 41.85 40.5 
Maximum Dose Thresholds 
Structure Criteria Dose (Gy) Target Volume Acceptable Volume 
PTV 47.25 10% 15% 
 49.50 5% 10% 
 51.75 0% N/A 
Bladder 40 40% 55% 
 45 15% 30% 
 50 0% 0% 
Femoral Heads 40 45% 65% 
 45 25% 40% 
 50 0% 0% 
Small Bowel 35 180 cc 230 cc 
 40 100 cc 130 cc 
 45 65 cc 90 cc 
 
Plans enrolled in the clinical trial were 
anonymously stored on the American 
College of Radiology (ACR) database and 
accessed through remote access to the 
Philadelphia server.  From this server, plan 
DVH’s were manually analyzed within the 
MIM (MIMsoftware Inc, Cleveland, OH 
44122) workspace and compared against the 
RTOG 0822 criteria.  These plans were then 
imported from MIM into ACR’s Eclipse 
platform and planned using the Eclipse CAP 
– 6X Linac with Dose Dynamic MLC.  Dose 
estimation and IMRT optimization was 
performed using the AAA_13714 and 
PO_13714 models, respectively.  The 
planning and dose optimization performed 
in this study was used with these settings 
and beam characteristics.  Plans which met 
the RTOG 0822 target criteria were labelled 
as high-quality and used for initial training 
of the model described in this paper, since 
they are more likely to be associated with a 
positive patient outcome [10]. 
 
 
3.2 RapidPlan Model Construction  
and Optimization 
 
Of the 97 IMRT plans were enrolled in the 
RTOG 0822 clinical trial, 39 of them were 
either not treated with 6X photons or could 
not be imported into Aria, and thus were not 
included in the 6X IMRT rectal model 
created in this paper.  Of the remaining 58 
treatment plans, 26 met all of the target 
criteria, and were thus considered high-
quality plans.  Each of these plans met the 
protocol’s prescribed 45 Gy to the rectal 
target without the need of scaling or 
normalization.  These 26 plans were used to 
create the initial iteration of the rectal model 
described in this paper.  While this count 
met the 20 required plans to create a 
RapidPlan model and provide a good 
amount of geometry variance, an effort was 
made to increase the number of plans in the 
model’s training library while still adhering 
to the target compliance metric. 
Upon every new trained iteration of the 
model, all of the 6X IMRT plans enrolled in 
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the clinical trial were reoptimized by the 
newly trained model.  This included both the 
low-quality plans which did not meet the 
target criteria as well as the high-quality 
plans used to initially train the model.  Since 
most of the low-quality plans met the 
acceptable variation criteria, an additional 
12 geometries were able to be re-optimized 
to reach high-quality, greatly increasing the 
distribution of geometries in the training 
library.  If a high-quality plan was improved 
via this cyclical re-optimization, the model-
created plan was submitted to the model’s 
training library alongside the initial enrolled 
IMRT plan.  If a subsequent re-optimization 
resulted in a higher plan quality than the 
previous re-optimization plan for a given 
geometry, the lower-quality plan would be 
replaced in the training pool.   
If both the newly iterated and previous 
DVH’s met RTOG target criteria, the 
significant differences in plan quality 
between them was evaluated by a net 
summation of normalized dosimetric 
differences, as described by Equation 1.  
Dose differences were calculated at each 
criteria volume mark and converted to a 
ratio by diving by the average dose between 
the two plans and the given volume mark’s 
target dose, as listed in Table 1.  As seen, the 
closer a dose point change is to the target 
criteria, the more weighted the ratio.  These 
normalized ratios are summed together, to 
give a simplified evaluation of if plan 
quality increased in reference to the RTOG 
criteria, with a positive summation 
suggesting plan quality increase, and a 
negative summation suggesting plan quality 
decrease.  PTV dose homogeneity, dose 
conformity, isodose curves, and normal 
tissue dose were also qualitatively evaluated 
to ensure plan quality.  If there was no 
significant plan quality increase, the 
previous plan was not replaced. 
 
Equation 1: Quantitative difference in plan quality 
weighted by RTOG criteria proximity 
 
𝑄𝐷𝑖𝑓𝑓 = ∑ ( ∑ 𝑍𝑖𝑗
𝑁𝑐𝑟𝑖𝑡𝑖
𝑗=1
)
𝑁𝑂𝑟𝑔
𝑖=1
+ 𝑍𝑃𝑇𝑉𝑈𝑝𝑝𝑒𝑟  
 
𝑍𝑖𝑗 =
𝐷𝑃𝑟𝑒𝑣𝑖𝑗 − 𝐷𝑁𝑒𝑤𝑖𝑗
|
𝐷𝑃𝑟𝑒𝑣 𝑖𝑗 + 𝐷𝑁𝑒𝑤 𝑖𝑗
2 − 𝐷𝑐𝑟𝑖𝑡𝑒𝑟𝑖𝑎𝑖𝑗|
 
 
𝑍𝑃𝑇𝑉𝑈𝑝𝑝𝑒𝑟 =
𝐷98𝑁𝑒𝑤 − 𝐷98𝑃𝑟𝑒𝑣
|
𝐷98𝑃𝑟𝑒𝑣 + 𝐷98𝑁𝑒𝑤
2 | − 45 𝐺𝑦
 
 
This process was cyclically repeated for 
every new instance of the model until an 
equilibrium of re-optimized plan quality 
was reached. 
 
3.3 Model Inputs 
 
Along with training from the clinical plans 
submitted to the RTOG clinical trial, the 
model was also trained and optimized using 
a set of manual dosimetric optimization 
goals.  This was to focus optimization and 
plan quality improvements on the RTOG 
target criteria, increasing the number of 
geometries used in model training.  For 
OAR dose sparing constraints, optimization 
goals were set at the target criteria volumes 
at 5 Gy below the target criteria dose to tend 
the resulting dose below the target 
thresholds.  Priority for these manual OAR 
constraints was determined by the model 
alongside the continuous optimization 
objective.  It should be noted that these OAR 
point objectives did not impact the result 
IMRT DVH nearly as significantly as the 
continuous optimization objectives 
produced by RapidPlan.    
While RapidPlan can also create 
continuous optimization objectives for the 
PTV, this was found to produce variable to 
non-desirable results.  To mitigate PTV dose 
coverage variation, manual optimization 
objectives with set priorities were 
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implemented for the PTV.  These objectives 
ensured that plans both met RTOG target 
criteria and resulted in conformality index 
values approximately equal to 1.  Normal 
tissue sparing was also manually set to 
produce consistently good dose falloff from 
the PTV and eliminate dose hotspots outside 
of the PTV. 
 
3.4 Model QA Validation 
 
Dosimetric analysis was performed to 
quantify the effects of re-optimization on 
plan quality, and thus patient outcome.  Plan 
quality was determined using Equation 1 
with the RTOG 0822 target criteria 
described in Table 1.  This was performed 
for and summed over every OAR and PTV 
target criteria for a given patient, with a 
positive value indicating an increase in plan 
quality and a negative value indicating a 
decrease.  Dose homogeneity, isodose curve 
geometry, and normal tissue sparing were 
qualitatively judged alongside this 
quantitative metric if a plan iteration was of 
approximately equal quantitative quality as 
its previous iteration.   
 
4 Results and Discussion 
 
The results of the dosimetric analysis of 
both the plans enrolled into RTOG 0822 and 
the plans reoptimized by the model 
discussed in this paper are listed in Table 3.  
This shows the number of plans from each 
set that met the RTOG target criteria, the 
acceptable variation criteria, and neither 
criteria (resulting in a failure).  As seen, the 
dose estimation model significantly 
increased the number of plans which met the 
target criteria, raising it from 26 of the 
enrolled plans to 39 of the reoptimized 
plans.  However, it should be noted that 
model reoptimization also slightly increased 
the number of plans which failed both the 
target and acceptable variation criteria, 
raising this number from 9 to 10.  This 
suggests that the model was successful in 
increasing the plan quality of low-quality 
rectal IMRT plans. 
 
4.1 Model Training 
 
The model was able to be successfully 
trained and raised to an equilibrium of 
quality through iterative reoptimization 
using both enrolled and reoptimized high-
quality plans.  A total of 40 patient 
geometries were used in model training.  
The model was trained to estimate dose for 
the OAR’s specified by RTOG 0822, as well 
as the individual femoral heads.  This was to 
ensure that one of the femoral heads was not 
getting a significantly higher dose than the 
other, a piece of data otherwise lost when 
evaluated as a single structure.  The results 
of this training are shown in Table 2.   
 As seen, the training successfully 
correlated the principle components of all 
the OAR’s used in training.  It should be 
noted that while the bladder was 
successfully trained, as seen in the very 
good χ2 value, a significant PTV/bladder 
overlap variability among the patient 
geometries resulting in a lower R2 value for 
principal component correlation.  While this 
produced slight EDVH issues towards 
higher dose regions, as seen in Figure 2, 
negligible estimated dose errors were 
observed for the patient geometries 
evaluated in this study.  
 
Table 2: Model Training Statistics 
Organ Trained R2 χ2 
Bladder Yes 0.517 1.101 
Small Bowel Yes 0.835 1.132 
Femoral Heads Yes 0.701 1.090 
Femoral Head 
[L] 
Yes 0.688 1.074 
Femoral Head 
[R] 
Yes 0.676 1.069 
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Figure 4: Geometric plots of the bladders used in 
model training (upper) and the principal component 
estimation residual plot (lower) 
4.2 Model Optimization and 
Validation 
 
Results of model reoptimization are shown 
below in Table 3.  As seen, there is a 
significant increase in the number of plans 
which met target criteria as compared to the 
original plans enrolled in RTOG 0822.  It 
should be noted that one of the enrolled 6X 
IMRT plans could not be reoptimized in 
RapidPlan due to software issues.  While 
this plan was not included in the statistics 
for the enrolled plan quality count, 
reoptimization plan count, and model 
validation evaluation. 
 For the reoptimized plans, the 
performance per organ is listed below in 
Table 4 and 5.  As seen, the RapidPlan 
model consistently met the RTOG OAR and 
PTV criteria, raising many of the organs up 
to either target or acceptable variation 
criteria.  This improvement occurred for all 
of the OAR’s specified in RTOG 0822 
except for the femoral heads, which were 
always within the RTOG target constraints 
for both the enrolled and reoptimized plans. 
 
Table 3: Count of plans that met RTOG 0822 criteria 
RTOG 0822 Criteria Enrolled Plans Reoptimized Plans Quality Count Diff 
Target 26 (44.8%) 39 (67.2%) +13 (+22.4%) 
Acceptable 23 (39.7%) 9 (15.5%) -14 (-24.1%) 
Failed 9 (15.5%) 10 (17.2%) +1 (+1.7%) 
 
Table 4: Number of reoptimized plans which met quality per organ 
Criteria PTV Bladder Femoral Heads Small Bowel 
Target 50 (86.2%) 49 (84.5%) 58 (100%) 53 (91.4%) 
Acceptable 0 (0%) 6 (10.3%) 0 (0%) 5 (5.2%) 
Fail 8 (14%) 3 (5.2%) 0 (0%) 0 (0%) 
 
Table 5: Organs where model reoptimization caused plan quality changes 
Organ Raised to  
Target 
Raised to  
Acceptable 
Reduced to  
Acceptable 
Reduced to  
Fail 
Net Quality  
Increase 
PTV 7 1 0 7 +1 (+1.7%) 
Bladder 11 0 2 2 +7 (+12.1%) 
Femoral Heads 0 0 0 0 0 (+0%) 
Small Bowel 4 1 0 1 +2 (+3.4%) 
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For cases where the RTOG constraint on the 
PTV was broken, this failure was often due to 
over-exposure in the PTV at 15% and 10% 
volume in order to maintain a high dose at 98% 
volume while preserving surrounding organs.  
This is likely the result of placing manual 
constraints on the PTV and not allowing the 
model to directly change these optimization 
goal priorities.  In cases such as these, it is up to 
the dosimetrist and physician to decide how 
much they are willing to underdose the PTV or 
further expose OAR’s.  In cases where plan 
quality was reduced due to OAR constraints 
(either to acceptable variation criteria or 
failure), this was often due to increased OAR 
dose to maintain homogenous dose over the 
PTV.  While this is labeled a reduction in plan 
quality by the metric used in this paper, this risk 
tradeoff between the PTV and OAR’s should be 
evaluated on a patient-by-patient basis during 
treatment planning.  Below, Figure 5 shows an 
example of the model improving a low quality 
DVH to high quality. 
 
Figure 5: Comparison of original enrolled plan DVH 
(squares) against the reoptimized plan DVH (triangles).  
The organs shown in this figure are the PTV (pink), 
bladder (yellow [right pair]), small bowel (blue), and 
femoral heads (yellow [left pair]). 
 
 
 
5 Conclusion 
 
A KBP model was developed using Varian’s 
RapidPlan software platform and designed for 
dose estimation of locally advanced rectal 
tumors treated with 6X IMRT.  The model 
described in this paper was initially created 
using 26 high-quality 6X plans enrolled in the 
RTOG 0822 clinical trial.  Additional plans 
among the enrolled RTOG plans were raised to 
high-quality through model-based iterative 
reoptimization and implementation into the 
model’s training library until an equilibrium of 
model-produced plan quality was achieved.  
Through this iterative method, an additional 12 
geometries were available for the model to use 
in EDVH training. 
Applying model reoptimization to the plans 
enrolled in the RTOG exhibited a 22.4% 
increase in the number of plans that met target 
criteria.  Specifically, the model exhibited 
significant dose sparing to the bladder and small 
bowel.  However, the model was shown to 
exhibit overexposure in the PTV in cases of 
difficult OAR sparing, albeit for a minority of 
cases.  While the ability to produce a high-
quality plan can vary from patient to patient, the 
model introduced in this paper has been shown 
to consistently produce a plan of equal or greater 
quality than the RTOG-enrolled plan, and can 
be used as an effective tool for planning QA of 
rectal IMRT cases. 
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